Psychiatry & Neurology Doctors in Salem, NH Accepting Medicare

3 Psychiatry & Neurology doctors found. Showing 1 - 3

Kevin J Dicesare, MD Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 44 Stiles Rd, Salem, NH 03079 Phone: 603-893-3548    Fax: 603-898-4779

Dr. James A Whitlock, M.D. Psychiatry & Neurology - Neurology Medicare: Not Enrolled in Medicare Practice Location: 70 Butler St, Salem, NH 03079 Phone: 603-893-2900    Fax: 603-898-4361

Dr. Karina Tamir, D.O. Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 30 Tuscan Blvd, Salem, NH 03079 Phone: 978-238-0333

News Archive

PinnacleHealth's new technology helps protect patients from risk of stroke during TAVR

PinnacleHealth is the first hospital in Pennsylvania and one of the first 10 in the country to introduce new technology shown to help protect patients from the risk of stroke during transcatheter aortic valve replacement (TAVR).

Duration of ibuprofen use may reduce risk of bladder cancer in northern New England patients

Dartmouth researchers have found that duration of ibuprofen use was associated with a reduced risk of bladder cancer in patients in northern New England, which has a high mortality rate of this disease. In a 2012 collaborative project with the National Cancer Institute, Margaret Karagas, PhD, co-director, Cancer Epidemiology & Chemoprevention program at Norris Cotton Cancer Center, and Professor of Community and Family Medicine at the Geisel School of Medicine at Dartmouth, and Richard Waddell, D.Sc, Research Assistant Professor of Medicine at the Geisel School of Medicine, looked for connections between ibuprofen use and bladder cancer.

Immune system may target other remote areas of the brain to improve stroke recovery

New University of Kentucky research shows that the immune system may target other remote areas of the brain to improve recovery after a stroke.

Columbia Laboratories to sell progesterone related assets and 11.2M shares to Watson Pharmaceuticals

Columbia Laboratories, Inc. has entered into a definitive agreement to sell substantially all of its progesterone related assets and 11.2 million shares of common stock to Watson Pharmaceuticals, Inc. for a $47 million upfront payment plus royalties of 10 to 20 percent of annual net sales of certain progesterone products. Additional payments up to $45.5 million can be earned by the successful completion of clinical development milestones in the ongoing PREGNANT Study, regulatory filings, receipt of regulatory approvals and product launches.

Medicare system aimed at improving care, lowering costs may not be having as much impact as thought

As the Medicare system seeks to improve the care of older adults while also keeping costs from growing too fast, a new University of Michigan study suggests that one major effort may not be having as much of an impact as hoped.

Read more Medical News

› Verified 2 days ago